Litcius/Paper detail

High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

A. Zapatero, A. Guerrero, Xavier Maldonado, A. Álvarez, Carmen González‐San Segundo, María Ángeles Cabeza Rodríguez, Josep María Macias i Solé, Agustí Pedro Olivé, Francesc Casas, A. Boladeras, C. Martín de Vidales, M. L. Vázquez de la Torre, Susana Vara, Juan Luis Sanz, Felipe A. Calvo

2022The Lancet Oncology44 citationsDOI

Topics & Concepts

MedicineAndrogen deprivation therapyProstate cancerFlutamideRadiation therapyAndrogenConcomitantBicalutamideAndrogen suppressionUrologyRandomizationInternal medicineRandomized controlled trialOncologyCancerHormoneAndrogen receptorProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchAdvanced Radiotherapy Techniques
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial | Litcius